Immune function in newborns with in-utero exposure to anti-TNFα therapy

Batia Weiss1,2*, Shomron Ben-Horin2,3, Atar Lev2,4, Efrat Broide2,5, Miki Yavzori2, Adi Lahat2,3, Uri Kopylov2,3, Orit Picard2,3, Rami Eliakim2,3, Yulia Ron2,6, Iris Avni-Biron2,7, Anat Yerushalmy-Feler2,8, Amit Assa9,10, Raz Somech2,4,11 and Ariella Bar-Gil Shitrit10,12

Background and aim: Anti-TNFα is measurable in infants exposed in utero up to 12 months of age. Data about the exposure effect on the infant’s adaptive immunity are limited. We aimed to prospectively evaluate the distribution and function of T and B cells, in infants of females with inflammatory bowel disease, in utero exposed to anti-TNFα or azathioprine.

Methods: A prospective multi-center study conducted 2014–2017. Anti-TNFα levels were measured in cord blood, and at 3 and 12 months. T-cell repertoire and function were analyzed at 3 and 12 months by flow-cytometry, expression of diverse T cell receptors (TCR) and T-cell receptor excision circles (TREC) quantification assay. Serum immunoglobulins and antibodies for inactivated vaccines were measured at 12 months. Baseline clinical data were retrieved, and 2-monthly telephonic interviews were performed regarding child infections and growth.

Results: 24 pregnant females, age 30.6 (IQR 26.5–34.5) years were recruited, 20 with anti-TNFα (infliximab 8, adalimumab 12), and 4 with azathioprine treatment. Cord blood anti-TNFα was higher than maternal blood levels [4.3 (IQR 2.3–9.2) vs. 2.5 (IQR 1.3–9.7) mcg/ml], declining at 3 and 12 months. All infants had normal number of B-cells (n = 14), adequate levels of immunoglobulins (n = 14), and protecting antibody levels to Tetanus, Diphtheria, Hemophilus influenza-B and hepatitis B (n = 17). All had normal CD4+, CD8+ T-cells, and TREC numbers. TCR repertoire was polyclonal in

CITATION
Weiss B, Ben-Horin S, Lev A, Broide E, Yavzori M, Lahat A, Kopylov U, Picard O, Eliakim R, Ron Y, Avni-Biron I, Yerushalmy-Feler A, Assa A, Somech R and Bar-Gil Shitrit A (2022) Immune function in newborns with in-utero exposure to anti-TNFα therapy. Front. Pediatr. 10:935034. doi: 10.3389/fped.2022.935034

COPYRIGHT
© 2022 Weiss, Ben-Horin, Lev, Broide, Yavzori, Lahat, Kopylov, Picard, Eliakim, Ron, Avni-Biron, Yerushalmy-Feler, Assa, Somech and Bar-Gil Shitrit. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
18/20 and slightly skewed in 2/20 infants. No serious infections requiring hospitalization were recorded.

**Conclusion:** We found that T-cell and B-cell immunity is fully mature and immune function is normal in infants exposed in utero to anti-TNFα, as in those exposed to azathioprine. Untreated controls and large-scale studies are needed to confirm these results.

**KEYWORDS**

vaccination response, T-cell function, T-cell receptor excision circles, immunoglobulins, anti-TNFα, azathioprine

### Introduction

Women with inflammatory bowel diseases (IBD) often require biologic therapy with anti-tumor-necrosis-factor-α (anti-TNFα) medications during their reproductive years to control disease activity and optimize pregnancy outcomes; however, some anti-TNFα medication cross the placenta and drug level may be measurable in the infant's blood up to 1 year (1, 2). This fact raised major concerns about the long-term impact of in utero exposure to anti-TNFα on the neonatal immune system and risk of infections (3, 4). A case from 2010, reporting death of an infant exposed in utero to biological therapy who received at age 3 months the Bacillus-Calmette-Guerin vaccine, together with the evidence of drug persistence in the infants, have led to the current recommendation to avoid live vaccines in infants exposed in utero to anti-TNFα medications (5, 6). In-depth data about the effect of anti-TNFα exposure of newborns on their adaptive immunity, including humoral, and cellular components, are limited and the results are conflicting (7–13).

Azathioprine exposure during pregnancy was not associated with fetal outcomes or increased infection risk during the first year, and no serum metabolites were detected 6 weeks after delivery (14).

In addition to the assays available for evaluation of the capacity of T and B-cell immunity (15–21), a sensitive and specific surrogate marker to assess both number and function of T-cells is T-cell receptor excision circles (TREC) quantification assay (18, 19). TRECs are formed during T-cell receptor gene rearrangement in developing T-lymphocytes (TREC) in the thymus, and therefore, are a marker for recently formed TREC. Absence or markedly reduced TREC levels indicate a low level of newly formed TREC or clonally expanded T-cells, and therefore are used as a screening test in Israel for severe type of T-cell immunodeficiency since 2015 (20, 21).

Herein, we aimed to prospectively evaluate the distribution and function of T-cells, immunoglobulin levels and the response to inactivated vaccines, from birth to 12 months of age in infants of females with IBD exposed to anti-TNFα in utero, compared to azathioprine exposure.

### Materials and methods

#### Study design

Consecutive pregnant females attending the participating centers, with an established IBD diagnosis, treated with anti-TNFα or AZA/6MP were offered to participate in a prospective multicenter study from January 1st 2014 till December 31st 2017. Upon obtaining an informed consent, the patients provided demographic details, disease characteristics, and medication history. Enrollment could occur at any point during pregnancy, and the medical treatment was continued according to the treating gastroenterologist’s decision, irrespective of the study. Disease activity during pregnancy was defined according to the treating gastroenterologist’s decision, irrespective of the study. Disease activity during pregnancy was defined according to the treating gastroenterologist’s decision, irrespective of the study.

At delivery, two samples of cord blood and one sample of maternal blood for anti-TNFα serum levels were collected. Additional samples were drawn at age 3 months for anti-TNFα drug level, and T-cell repertoire and function, and at age 12 months for T-cell repertoire and function, serum immunoglobulin levels and antibody titers for inactivated vaccines: Anti-Hbs, HiB, tetanus toxoid and diphtheria. Infants exposed to AZA/6MP underwent the same tests except drug levels. Clinical data including demographics, IBD history, medications, gestational and delivery details, were retrieved from the medical charts. A telephonic infant follow-up was performed every 2 months, including growth data, history of febrile diseases, infections, hospitalizations, immunizations, medications, developmental milestones, and the presence of new medical conditions or malformations. The immunization schedule in Israel includes hepatitis B vaccines at birth, ages 1–2 and 6 months; diphtheria–tetanus–pertussis, inactivated polio vaccine, and rotavirus at 2, 4, 6 months; HiB at 2, 4, 6, 12 months and Pneumococcal vaccine at 2, 4, and 12 months.
Since no untreated IBD females could be recruited as controls, we retrospectively obtained results of the newborn screening for TREC number at delivery from 8 infants of untreated women with IBD and compared them to the TREC number at delivery of the study groups.

The study was approved by the ethical committees of the participating hospitals.

**Laboratory tests**

Cord blood and maternal blood for anti-TNFα levels (Infliximab or Adalimumab) and antibodies to anti-TNFα were obtained in SST- serum separator tubes, refrigerated at 4°C and delivered in 4°C to a central laboratory at Sheba Medical Center. Infliximab and adalimumab drug and antibodies levels were measured by employing the previously described infliximab or adalimumab ELISA assay, developed at Sheba’s gastroenterology laboratory (22, 23).

Absolute numbers and percentages of lymphocytes were quantified by assessment of cell surface markers using immunofluorescent staining and flow cytometry (Epics V; Beckman Coulter, Hialeah, FL, United States) with antibodies purchased from Beckman Coulter. TREC in Guthrie cards was detected through the Israeli SCID newborn screening program that uses the commercial EnLite™ Neonatal TREC kit (Wallac Oy, Mustionkatu 6, FI-20750 Turku, Finland), as previously described (21). The following TREC analysis was performed on peripheral blood by using DNA extracted from the study patients’ PBMCs. The amount of signal joint (sj) TREC copies per DNA content was determined by real-time quantitative PCR as previously described (24). Surface expression of individual TCRVβ families was analyzed using flow cytometry and a set of TCRVβ specific fluorochrome labeled monoclonal antibodies as previously described (24). Normal control values were obtained from the IOTest Beta Mark-Quick Reference Card (Beckman Coulter).

B-cell function was determined using quantification of the immunoglobulin isotypes and specific antibody responses to immunizations.

At age 12 months, serum IgG, IgM, and IgA were measured using standard nephelometry. A sample of 3 mL infants’ blood was used for measurement of serologic titers for tetanus toxoid (VaccZyme Human Anti Tetanus Toxoid IgG EIA kit, Binding site), Hib (VaccZyme Human Anti Haemophilus Influenza EIA kit, Binding site) and diphtheria (VaccZyme Human Anti Diphtheria Toxoid IgG EIA kit, Binding site), at the immunology laboratory, Sheba medical center, according to the manufacturer instructions. Serologic titers of anti-HBs antibodies were performed using ARCHITECT Anti-HBs (Abbott Ireland, Diagnostics Division, Sligo, Ireland) at the Gastroenterology laboratory.

The comparison of the different immunologic studies performed in the study groups was to standard laboratory normal ranges.

**Statistical analysis**

Continuous variables are presented as median with interquartile range (IQR). Categorical variables are presented as N (%). Differences between groups were assessed using a Fisher’s exact test and Kruskal–Wallis test, for categorical and continuous data, respectively. A P-value of < 0.05 was considered statistically significant. Statistical analyses were performed using SAS 9.4 software (Cary, NC, United States).

**Results**

Twenty-four pregnant females, 20 with anti-TNFα (infliximab 8, adalimumab 12) and 4 with azathioprine treatment, were recruited from 5 hospitals in Israel. The clinical and demographic characteristics of the patients are shown in Table 1. Additional medications to anti-TNFα included azathioprine (n = 3), 5-ASA (n = 3), and corticosteroids (n = 1). Therefore, we present the results of combination therapy of anti-TNFα and azathioprine as a separate group. Anti-TNFα was discontinued between weeks 24–34 in 15, and continued throughout pregnancy in 5 females (3 infliximab, 2 adalimumab), with no difference in discontinuation time between infliximab and adalimumab (median 30, IQR 30–32 vs. 29.5, IQR 25–32, p = 0.53). At delivery the median cord blood level and maternal blood level were 4.3 (IQR 2.3–9.2) and 2.5 (IQR 1.3–9.7) mcg/ml, respectively (p = 0.06). Maternal levels were higher in infliximab than adalimumab treated females [median 10.4 (IQR 4.3–15.4), 1.3 (IQR 0.3–2.5), p = 0.002], with corresponding higher cord blood levels [median 8.8 (IQR 4.5–13.5), 1.3 (IQR 0.3–2.5) mcg/ml, p = 0.02]. At ages 3 (n = 13) and 12 months (n = 15), the median infants’ blood levels were 0.36 (IQR 0.1–1.34) mcg/ml and 0.06 (IQR 0.04–0.1) mcg/ml, respectively.

Not all newborns had blood samples available at both time points due to mothers’ refusal (n = 4 at age 3 months) and/or paucity of blood quantity withdrawn (9 infants at 3 months, 6 infants at 12 months). Only 4 mothers refused infants’ blood testing at age 3 months, but agreed at age 12 months. All had evaluation of the T-cell function at least once (Figure 1).

**Pregnancy outcome and newborn follow-up**

Two infants exposed to anti-TNFα were born preterm (gestational weeks 30.36, birth weights 1,300, 2,480 gr). Two
TABLE 1 Demographic and clinical characteristics of the study group.

|                               | Total N = 24 | Anti-TNFα N = 17 | Azathioprine N = 4 | Anti-TNFα + Azathioprine N = 3 | P    |
|-------------------------------|--------------|------------------|--------------------|-------------------------------|------|
| Age at pregnancy [years, (median, IQR)] | 32.2 (27.0–34.6) | 30.1 (26.1–33.4) | 33.7 (33.3–35.9) | 35.0 (26.1–33.4) | 0.06 |
| Diagnosis                     |              |                  |                    |                               |      |
| Crohn’s disease               | 15           | 9                | 3                  | 3                             | 0.59 |
| Ulcerative colitis            | 8            | 7                | 1                  | 0                             |      |
| IBD-Undetermined              | 1            | 1                | 0                  | 0                             |      |
| Age of diagnosis [years, (median, IQR)] | 21.5 (18.0–26.5) | 20 (18.0–24.5) | 25.5 (21.5–29.0) | 27.0 (15.0–27.0) | 0.25 |
| Disease activity (pregnancy), N (%) |              |                  |                    |                               |      |
| Remission                     | 19 (79)      | 13 (76.5)        | 4 (100)            | 2 (66.7)                      | 0.76 |
| Mild                          | 4 (16.7)     | 3 (17.6)         | 0                  | 1 (33.3)                      |      |
| Moderate                      | 0            | 1 (5)            | 0                  | 0                             |      |
| Delivery mode, N (%)          |              |                  |                    |                               |      |
| Vaginal                       | 12 (50)      | 9 (52.9)         | 2 (50)             | 1 (33.3)                      | 0.82 |
| Cesarean                      | 12 (50)      | 8 (47.1)         | 2 (50)             | 2 (66.6)                      |      |
| Delivery week (median, IQR)   | 38.9 (38.0–39.7) | 38.8 (38.0–39.5) | 39.4 (38.5–40.3) | 37.4 (37.4–38)               | 0.082|

FIGURE 1

Immune function tests performed at each age of the study groups.
TABLE 2 Pregnancy outcome and 12-month follow-up of infants exposed in utero to anti-TNFα, azathioprine or combination therapy.

| N (%) | Total N = 24 | Anti-TNFα N = 17 | Azathioprine N = 4 | Anti-TNFα + Azathioprine N = 3 | P |
|-------|--------------|------------------|-------------------|-----------------------------|---|
| Male gender |
| 14 (58) | 8 (47.1) | 3 (75) | 3 (100) | 0.17 |
| Birth weight [Kg (median, IQR)] |
| 3.0 (2.6–3.4) | 3.1 (2.7–3.4) | 3.1 (2.7–3.7) | 2.0 (2.0–3.1) | 0.22 |
| Congenital malformations* |
| 1 (4.2) | 1 (5.9) | 0 | 0 | 0.80 |
| Post-natal antibiotics |
| 6 (25) | 3 (17.6) | 1 (25) | 2 (66.7) | 0.20 |
| Phototherapy |
| 2 (8.7) | 2 (10) | 0 | 0 | 0.62 |
| Breast feeding - 3 mon |
| Full | 9 (38) | 7 (41.2) | 2 (50) | 0 | 0.35 |
| Partial | 4 (16.7) | 3 (17.6) | 1 (25) | 0 | 0 |
| Weight - 12 mon [Kg (median, IQR)] |
| 9.8 (8.7–10.2) | 9.7 (8.9–10.1) | 9.3 (8.3–10.3) | 10.2 (9.5–10.2) | 0.67 |
| Height - 12 mon [Cm (median, IQR)] |
| 75.0 (73.0–77.6) | 75.0 (72.0–77.0) | 76.3 (74.0–77.8) | 76.5 (73.6–79.0) | 0.53 |
| Immunizations -12 mon |
| DTP + Hib* |
| None | 1 (4.2) | 0 | 1 (25) | 0 | 0.38 |
| 2 doses | 2 (8.3) | 2 (11.8) | 0 | 0 | 0 |
| 3 doses | 20 (83.3) | 14 (82.4) | 3 (75) | 3 (100) | 0 |
| 4 doses | 1 (4.2) | 1 (5.9) | 0 | 0 | 0 |
| Hepatitis B |
| None | 1 (4.2) | 0 | 1 (25) | 0 | 0.23 |
| 2 doses | 1 (4.2) | 1 (5.9) | 0 | 0 | 0 |
| 3 doses | 22 (91.7) | 16 (94.1) | 3 (75) | 3 (100) | 0 |
| Rota virus |
| None | 9 (37.5) | 8 (47.1) | 1 (25) | 0 | 0.46 |
| 1 dose | 2 (8.3) | 2 (11.8) | 0 | 0 | 0 |
| 2 doses | 1 (4.2) | 1 (5.9) | 0 | 0 | 0 |
| 3 doses | 12 (50) | 6 (35.3) | 3 (75) | 3 (100) | 0 |

*Left pelvic kidney.
DTP, diphtheria, tetanus, pertussis; Hib, hemophilus influenza.

TABLE 3 Acquired infections of the newborns during 12 months follow-up.

| Infection | Total no. of episodes |
|-----------|-----------------------|
|           | 0–6 months | 6–12 months |
| URTI* (± fever) | 8 | 3 | 5 |
| Otitis media | 7 | 1 | 6 |
| Conjunctivitis | 4 | – | 4 |
| Aphthous stomatitis | 3 | – | 3 |
| Pneumonia | 2** | – | 2 |
| Fever/Rash | 7 | 2 | 5 |
| Pertussis** | 1 | – | 1 |
| Acute Gastroenteritis | 1 | 3 | 4 |

*URTII, upper respiratory tract infection.
**Maternal treatment: pneumonia 1- anti-TNFα, discontinued week 30; pneumonia 2- anti-TNFα, continued throughout pregnancy; pertussis- anti TNFα, continued throughout pregnancy.

minor congenital malformation (1 pelvic kidney, 1 umbilical cord containing 2 blood vessels) were diagnosed in infants exposed to azathioprine (Table 2).

Despite a recommendation to avoid live-vaccines with exposure to anti-TNFα, 9/20 (45%) infants received a full 3-dose Rota virus vaccination and 3 (15%) infants 1–2 vaccine doses by age 6 months, with no reported complications. One mother in the azathioprine group refused all immunizations.

There were no hospitalizations due to infections during the first year of life. Two infants exposed to anti-TNFα monotherapy (1 discontinued at week 30, 1 continued...
|                  | Anti-TNFα | Azathioprine | Anti-TNFα + Azathioprine |
|------------------|-----------|--------------|-------------------------|
|                  | *N = 17*  | *N = 4*      | *N = 3*                  |
|                  | *Age 3 months* | *Age 12 months* | *Age 3 months* | *Age 12 months* | *Age 3 months* | *Age 12 months* |
|                  | *N = 8*   | *N = 13*     | *N = 3*     | *N = 3*     | *N = 3*   | *N = 2*  |
| **WBC mm⁻³**     | Median, (IQR) | 11,475 (8,800–13,910) | 12,480 (10,390–14,690) | 6,565 (9,100–12,230) | 10,665 (9,340–14,690) | 10,110 (8,040–13,080) | 7,990 (6,850–9,130) | 0.78 *p*, 0.15 **p** |
| **T-cells subpopulations** | Median, (IQR) | Lymphocytes mm⁻³ | 6,701 (6,020–8,705) | 6,558 (5,260–8,295) | 5,327 (4,651–7,429) | 4,863 (3,977–5,748) | 6,703 (5,258–7,456) | 3,733 (2,836–4,629) | 0.47 *p*, 0.06 **p** |
|                  | CD3/mm⁻³ | 4,862 (4,177–5,301) | 4,067 (3,314–5,889) | 3,746 (3,191–4,886) | 3,452 (2,823–4,081) | 2,156 (1,193–2,480) | 938 (631–3,311) | 1,063 (737–1,389) | 0.51, 0.04 |
|                  | CD4/mm⁻³ | 3,770 (3,217–3,195) | 2,530 (2,209–3,155) | 2,772 (2,512–3,585) | 1,684 (1,380–1,988) | 2,156 (1,078–1,435) | 1,256 (1,078–1,435) | 0.06, 0.04 |
|                  | CD8/mm⁻³ | 1,135 (971–1,532) | 1,274 (915–2,427) | 1,023 (706–1,255) | 1,583 (636–2,529) | 1,542 (1,052–2,311) | 774 (482–1,065) | 0.96, 0.04 |
|                  | CD20/mm⁻³ | 1,433 (883–2,437) | 1,472 (1,399–1,746) | 1,094 (1,044–1,949) | 876 (716–1,035) | 1,452 (1,052–2,311) | 774 (482–1,065) | 0.96, 0.04 |
|                  | CD56 (neutral, NK) | 6.5 (4.0–8.5) | 7.00 (4.00–10.00) | 4.00 (3.5–4.5) | 5.00 (5.00–5.00) | 1.0 (1.0–5.0) | 3.0 (3.0–3.0) | 0.11, 0.25 |
| **TCR v-beta quantific** | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal | 0.24, 0.86 |
| **TREC**         | 7,280 (4,250–9,112) | 6,301 (2,842–7,654) | 7,998 (5,186–16,689) | 6,051 (4,323–7,538) | 9,974 (7,951–12,270) | 5,788 (2,842–8,734) | 0.24, 0.86 |
| **Immunizations** | **Anti-HiB Ab** | **Anti-Diphtheria Ab** | **Anti-Tetanus Ab** | **HbsAb** | **Immunoglobulins** |
|                  | mg/l | IU/ml | IU/ml | mg/dl | Median, (IQR) |
|                  | 0.5 (0.1–0.9) | 0.9 (0.2–5.2) | 0.2 (0.2–0.2) | 0.5 (0.2–1.6) | 0.3 (0.2–0.3) | 0.6 (0.4–0.7) | 0.63, 0.86 |
|                  | 0.3 (0.0–1.8) | 1.1 (0.6–2.3) | 0.0 (0.0–0.0) | 2.4 (0.1–4.7) | 0.9 (0.3–1.5) | 3.2 (0.7–5.7) | 0.25, 0.78 |
|                  | 0.1 (0.1–0.8) | 0.8 (0.3–1.4) | 0.1 (0.1–0.1) | 0.9 (0.3–1.5) | 0.3 (0.3–0.4) | 3.1 (1.6–4.6) | 0.64, 0.28 |
|                  | NA | 193.9 (29.0–1001.0) | NA | 50.2 (2.1–1001.0) | NA | 70.4 (68.7–72.0) | 0.95 **p** |
| **IgG**          | NA | 914 (812–1180) | NA | 699 (455–841) | NA | 787 (718–856) | 0.15 **p** |
| **IgA**          | NA | 50 (44–61) | NA | 36 (29–67) | NA | 52 (43–62) | 0.69 **p** |
| **IgM**          | NA | 75 (70–99) | NA | 99 (66–113) | NA | 94 (72–115) | 0.75 **p** |

*At age 3 months- available for 8 infants: 4- Anti-TNFα, 2- Anti-TNFα + azathioprine, 2- azathioprine.
**At age 3 months- available for 10 infants: 7- Anti-TNFα, 2- Anti-TNFα + azathioprine, 1- azathioprine.
***Hemophilus influenza B vaccine.
*p for age 3 months.
**p for age 12 month.
throughout pregnancy), had one event of pneumonia, and one was clinically diagnosed with pertussis despite immunizations, at age 10 months. Infants exposed to combination therapy did not have significant infections (Table 3). There was no correlation between the appearance of any infection and cord blood anti-TNFα level.

**Immune function**

All infants had normal B-cell numbers [3 months; median 3,913 (IQR 2,751–5,624), 12 months; 4,852 (IQR 4,014–8,716)], adequate immunoglobulin levels and normal protecting levels of antibodies to previous vaccinations (Table 5). The infant who developed pertussis despite vaccination had antibodies to other vaccination excluding possible dysfunctional B cell immunity. There was no correlation between umbilical cord anti-TNFα level and immunoglobulin levels or response to vaccination at ages 3 and 12 months.

All infants had normal levels of CD4+, CD8 + T-cells, and TREC during the first year of life (Table 5). In order to better assess the function of the T cell adaptive immunity, TCR repertoire analysis was performed. All, beside two infants exposed to anti-TNFα, had normal representation of polyclonal repertoire (Figure 2). Two infants had a slightly skewed repertoire, with no correlation to clinical outcomes, and similar anti-TNFα cord blood and serum levels to the other infants. We did not find significant longitudinal differences during the first year of life in each infant, suggestive a full mature T-cell immunity since infancy with exposure to anti-TNFα, azathioprine or combination therapy. At age 12 months, a numerical decrease in CD4 and CD20 cells was observed in infants exposed to combination therapy compared to monotherapy (Table 5). However, all differences were within the normal range cell number, with no difference between exposure to infliximab or adalimumab (Table 6). Anti-TNFα cord blood levels correlated negatively with CD4 T-helper cell number ($r = −0.85, p = 0.003, n = 9$) and positively with the number of CD8 T-cells ($r = 0.72, p = 0.02, n = 10$) at age 3 months but not 12 months ($r = −0.38, p = 0.27, n = 10$, and $r = −0.28, p = 0.43, n = 10$, respectively). Those differences, although
|                      | Infliximab | Adalimumab | Azathioprine | Anti-TNFα + Azathioprine | P        |
|----------------------|------------|------------|--------------|--------------------------|----------|
|                      | N = 7      | N = 10     | N = 4        | N = 3                    | N = 3    |
| WBC mm³               | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 11,990 (7,880–12,800) | 14,690 (13,440–16,520) | 10,960 (9,170–15,020) | 10,605 (10,140–12,865) | 9,595 (8,600–12,095) | 10,110 (8,040–13,080) |
|                      | Median, (IQR) |           |              |                          |          |
| T-cells subpopulations |            |            |              |                          |          |
| Lymphocytes mm³       | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 5,327 (4,651–7,429) | 5,327 (4,651–7,429) | 5,327 (4,651–7,429) | 5,327 (4,651–7,429) | 5,327 (4,651–7,429) |
|                      | Median, (IQR) |           |              |                          |          |
| CD3/mm³               | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 4,837 (3,298–5,618) | 4,887 (4,309–4,983) | 4,001 (3,659–4,855) | 3,746 (3,191–4,886) | 3,452 (2,823–4,081) |
|                      | Median, (IQR) |           |              |                          |          |
| CD4/mm³               | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 3,766 (2,864–4,668) | 3,770 (3,217–3,915) | 2,498 (2,289–3,324) | 2,772 (2,512–3,585) | 1,684 (1,380–1,988) |
|                      | Median, (IQR) |           |              |                          |          |
| CD8/mm³               | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 1,334 (1,039–1,726) | 1,091 (971–1,246) | 1,189 (1,003–1,851) | 1,023 (706–1,255) | 1,583 (636–2,529) |
|                      | Median, (IQR) |           |              |                          |          |
| CD20/mm³              | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 990 (776–2,383) | 1,239 (836–1,410) | 1,541 (1,326–2,491) | 1,530 (1,446–1,791) | 1,094 (1,044–1,949) |
|                      | Median, (IQR) |           |              |                          |          |
| CD56 (neutral, NK)    | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 3.00 (2.0–5.0) | 7.0 (4.0–10.0) | 8.0 (8.0–9.0) | 7.0 (4.4–10.0) | 4.0 (3.5–4.5) |
|                      | Median, (IQR) |           |              |                          |          |
| TCR v-beta quantific *|            |            |              |                          |          |
|                      | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal | Normal/polyclonal |
|                      | Median, (IQR) |           |              |                          |          |
| TREC                  | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 7,280 (6,332–7,814) | 6,565 (6,301–6,978) | 5,798 (3,523–9,112) | 3,310 (1,950–7,225) | 7,998 (5,186–16,689) |
|                      | Median, (IQR) |           |              |                          |          |
| Immunizations **      |            |            |              |                          |          |
| Anti–HiB Ab*** mg/l   | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 0.2 (0.2–0.2) | 0.6 (0.1–0.9) | 0.4 (0.2–3.0) | 0.2 (0.2–0.2) | 0.6 (0.2–0.3) |
|                      | Median, (IQR) |           |              |                          |          |
| Anti-Diphtheria Ab IU/ml | 3 mon   | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 0.1 (0.0–0.2) | 0.6 (0.3–1.8) | 0.7 (0.3–1.1) | 0.0 (0.0–0.0) | 2.4 (0.1–4.7) |
|                      | Median, (IQR) |           |              |                          |          |
| Anti-Tetanus Ab IU/ml | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 0.2 (0.1–0.4) | 0.1 (0.1–0.8) | 0.6 (0.4–0.9) | 0.1 (0.1–0.1) | 0.9 (0.3–1.5) |
|                      | Median, (IQR) |           |              |                          |          |
| HBsAb mIU/ml          | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
|                      | 29.0 (23.3–43.4) | NA | 404.5 (43.5–1001.0) | NA | 50.2 (2.1–1001.0) |
|                      | Median, (IQR) |           |              |                          |          |
| Immunoglobulins mg/dl |            |            |              |                          |          |
|                      | 3 mon      | 12 mon     | 3 mon        | 12 mon                   | 3 mon    |
|                      | N = 4      | N = 7      | N = 4        | N = 9                    | N = 3    |
| IgG                  | NA         | 914 (812–1,290) | NA | 942 (704–1,180) | NA | 699 (455–841) |
|                      | Median, (IQR) |           |              |                          |          |
| IgA                  | NA         | 50 (38–79) | NA | 53 (44–61) | NA | 36 (29–67) |
|                      | Median, (IQR) |           |              |                          |          |
| IgM                  | NA         | 75 (57–99) | NA | 75 (70–111) | NA | 99 (67–113) |
|                      | Median, (IQR) |           |              |                          |          |

*At age 3 months- available for 8 infants 4- Anti-TNFα, 2- Anti-TNFα + azathioprine, 2- azathioprine.
**At age 3 months- available for 10 infants: 7- Anti-TNFα, 2- Anti-TNFα + azathioprine, 1-azathioprine.
***Hemophilus influenza B vaccine.
∧p for age 3 months.
∧∧p for age 12 month.
statistically significant, were all within the normal range of the T-cell subsets number.

**Discussion**

We report a prospective and detailed immune function evaluation of infants of IBD patients, with prenatal exposure to anti-TNFα medications or azathioprine. We show, for the first time by a marker for recently formed TREC, that T-cell function is normal since birth and during follow-up. Although the main use of TREC is for exclusion of SCID and primary immune deficiencies, the normal number during the first year of life suggests, together with the measurement of T-cell subpopulations, a normal T-cell function. In addition, their B-cell number and functions are normal, with normal immunoglobulins levels and intact response to childhood vaccinations.

Children of mothers with IBD do not have an increased long-term risk for chronic or malignant diseases except IBD (25). While multiple studies reported safety of anti-TNFα medications regarding pregnancy outcomes (26–30), their influence on the immune system of the exposed infants is not completely resolved. The mechanism of action of anti-TNF antibodies is still a matter of debate, and differs between peripheral and mucosal cells, as well as in vivo and in vitro. Their effects are mediated through complex interactions with various immune cell populations involved in the pathogenesis of IBD (31, 32), and therefore, there is a rationale for testing the immune function of in utero exposed infants.

Bortlik et al. (10), followed 25 exposed children to age 34 months and reported normal antibody responses against tetanus, S. pneumonia, diphtheria, rubella, morbilli, and paritis ($n = 15$), but low antibodies to Hib in 6/15, mild reduction in immunoglobulin levels in 7/15 (41%), and normal lymphocyte subpopulation counts. However, the immunological tests were not performed within constant times from vaccination or from birth. Despite the recommendations, two thirds of the children received BCG vaccine but only 3 developed larger skin reaction and 1 had lymphadenopathy. Duricova et al. (12), reported an adequate antibody response for tetanus, diphtheria, streptococcus pneumonia, measles, and rubella in over 95% of infants, for Hib in 65% and for Mumps in 75% of 49 children exposed in utero to anti-TNFα compared to healthy controls, median ages 35 and 50 months. Fifteen infants received BCG vaccination within the first week of life, of them 4 developed large skin reactions and one axillar lymphadenopathy, compared to 2 of the controls. One report from the PIANO registry including 12 in utero exposed infants showed normal IgA and IgG levels, low IgM levels in 5/10 (50%), but a normal antibody response to tetanus and Hib vaccines at age 6–28 months in 92%, and no increase in infection rates (7). Another study from the same registry, found no difference in adequate antibody titers to Hib and tetanus between infants exposed or unexposed to anti-TNFα in utero; 71% of exposed ($n = 41$) and 50% of unexposed ($n = 8$), 80% ($n = 8$) and 75% ($n = 8$) of exposed and unexposed children, respectively (11). Importantly, 35 exposed infants received the Rotavirus vaccines, with reaction of fever in 6 and diarrhea in one, comparable to the general population. A recent French study (33) reported that 13% of infants exposed to anti-TNFα medications (43% throughout pregnancy) were vaccinated against tuberculosis before age 6 months, with no case of disseminated BCG infection, and 12 were vaccinated against Measles–Mumps–Rubella before age 9 months, with no events of severe infection. This study provides no data on the serum anti-TNFα levels in the exposed infants. A prospective small study of 7 exposed infants reported a normal number but less mature B and helper T-phenotype that normalized within 12 months, decreased T-reg cells at birth, and normal immunoglobulins, vaccine responses, and T-cell proliferation to mitogens. However, a decreased response after mycobacterial challenge at birth was noted, with no complete recovery after drug removal, suggesting that the immune system activation upon mycobacterial challenge may be compromised (9). Kattah et al. (8), used multiparameter flow cytometry on 22 infants with different in utero exposures from the PIANO registry at age 12 months; (1 = no exposure, 4 certolizumab, 11 infliximab/adalimumab, 4 infliximab/adalimumab/immunomodulator, 4 certolizumab/immunomodulator). In those small different exposure groups, B and T lymphocyte subsets were preserved in all, with no increased risk of infections.

There were no infections requiring hospitalizations in our group of infants, even in those exposed in the third trimester. Although we do not have a control group of infection rate in the first year of life, the number of 33 infections in 24 infants, without a need for hospitalization, is within normal limits (34). In a study from the Czech- Rebublic no increase in infection rate was found in children exposed to anti-TNFα, compared to unexposed infants of non-IBD mothers (12). A recent large population- based study reported a slightly increased rate of infections in anti-TNFα exposed infants, defined by hospital admissions for infection in the first year of life, as well as increased rates for antibiotic prescriptions in the second year of life. The incidence rate ratios for infections were similarly increased when treatment was stopped before or continued during the third trimester, and was not higher with combination therapy, compared to non-biological treatment exposure and the general population (35). In another large study from Denmark in utero exposure to anti-TNFβ but not to thiopurines resulted in an increased risk of respiratory and uro-gynecological infections during the first year (36). Both studies included infants of females with different inflammatory disorders, who may be incomparable to IBD patients. A recent
study of neonatal outcomes after fetal exposure to biologics, thiopurines, combination therapy or no treatment (IBD, 1,490 pregnancies) showed no difference in infection rate during the first year of life (30).

The advantages of our study are the prospective measurements of TREC, antibody responses to vaccines, immunoglobulin levels and serum drug levels, at exact intervals since birth, and a control group of immunomodulatory treatment alone. In contrast to previous studies, we show a completely normal antibody response and normal immunoglobulin levels in all infants. BCG is not part of the vaccination program in Israel, and the only first-year live vaccine is *Rota virus*. The TREC measurement is a novel method used in our study, allowing evidence of the intact T-cell immunity since early infancy. This reinforces the indirect evidence from previous studies in which live vaccines where administered despite recommendations, that live vaccines may be considered during the first year of life in infants exposed to anti-TNFα medications *in utero*. Indeed, in our study 12 (60%) infants received at least one dose of *Rota virus* vaccine with no complications. The debate about live vaccines in those infants should consider the risk of specific infections like tuberculosis, measles mumps rubella, and *Rota virus* in different geographic areas, and the risk-benefit ratio between disease acquirement and possible vaccine complications. Measurement of drug levels prior to vaccination can assess decision making (37). Larger studies and *in vitro* challenge investigations are needed in prior to changing the recommendations.

Our study has a few limitations. Firstly, our groups of patients and controls are still small and not all tests were performed at all points for every patient, a possible cause of bias. Previous studies included similar small control groups, due to recruitment difficulties in studies involving infant blood drawing. Secondly, we were not able to recruit untreated IBD females, due to maternal reluctance to perform blood tests to the infants. However, we were retrospectively able to compare the TREC number at birth of unexposed infants of IBD females to a small number of patients form the study, showing no difference in this aspect. Thirdly, we have not examined IL-12/IFN-γ levels, relevant to mycobacterial infection.

**Conclusion**

In conclusion, aspects of the adaptive immune system, including T-cell and B-cell functions were normal in infants exposed *in utero* to anti-TNFα, suggesting that a significant secondary immunodeficiency is unlikely. Further studies are required, examining response to mycobacterial challenge and the IL-12/IFN-γ pathway. We believe the live vaccine immunization schedule of anti-TNFα exposed infants, should be considered according to the geographic disease epidemiology, and the risk-benefit stratification.

**Data availability statement**

The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

**Ethics statement**

The studies involving human participants were reviewed and approved by the Ethics Committee Sheba Medical Center. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**Author contributions**

BW contributed to study concept and design, statistical analysis and interpretation of data, drafting of manuscript, and has approved the final draft submitted. SB-H contributed to study concept and design and critical revision of the manuscript. ALe performed the immunological tests. EB, ALa, UK, RE, YR, IA-B, AY-F, and AA contributed to patient recruitment, acquisition of data, and critical revision of the manuscript. MY and OP contributed to performance of immunological tests and critical revision of the manuscript. RS contributed to study concept and design and drafting of manuscript. AB-G contributed to study concept and design, patient recruitment, acquisition of data, and critical revision of the manuscript. All authors contributed to the article and approved the submitted version and approved the final draft submitted.

**Funding**

This study was supported by the Israel Gastroenterology Association.

**Conflict of interest**

BW received in the past lecture fee from Abbvie and consultation fee from Janssen. SB-H received consulting and advisory board fees and/or research support from AbbVie, MSD, Janssen, Takeda, Pfizer, Roche, GSK, and CellTrion. UK speaker and advisory fees- Jannsen Abbvie Takeda MSD Medtronic, research grants- Medtronic Janssen Takeda. RE speaker and advisory fees- Medtronic, Takeda; Research grant – Medtronic. AA speaker and advisory fees- Abbvie, Ferring.
research grants- Abbvie, Janssen. AB-G received consultancy fees and research grants from Takeda and Janssen and consultancy and speaking fees from Takeda, Janssen, Abbvie, Pfizer, Ferring and Neopharm.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease. Inflamm Bowel Dis. (2017) 23:1011–8. doi: 10.1097/MIB.000000000001102.

2. Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med. (2013) 11:174. doi: 10.1186/1741-7015-11-174.

3. Julsgaard M, Christensen LA, Gibson PR, Gearly RB, Fallborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. (2016) 151:110–9.

4. Cheent K, Nandan J, Sharga S, Khalo L, Pad A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. (2010) 4:603–5. doi: 10.1016/j.jcjo.2010.05.001.

5. van der Woude CJ, Arzidzoon S, Bengtson MB, Florint G, Fraser G, Katsanos K, et al. The second European evidence-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. (2015) 9:107–24.

6. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto consensus statements for the management of inflammatory bowel disease during pregnancy. Gastroenterology. (2016) 150:734–57. et doi: 10.1053/j.gastro.2015.12.003.

7. Sheihani S, Cohen R, Kane S, Dubinsky M, Church JA, Madhevan U. The effect of maternal peripartum anti-TNF-alpha use on infant immune response. Dig Dis Sci. (2016) 61:1622–7. doi: 10.1002/dads.26020-3992-2.

8. Kattah MG, Millush JM, Burt T, McCabe RP Jr, Whang MI, Ma A, et al. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter in pregnancy Gastroenterology. (2018) 9:143–54.

9. Esteve-Sole A, Deya-Martinez A, Texido I, Ricart E, Gompertz M, Torradeflot M, et al. Immunological changes in blood of newborns exposed to anti-TNFas during pregnancy. Front Immunol. (2017) 8:1123. doi: 10.3389/fimmu.2017.0.1123.

10. Bortlik M, Duricova D, Machkova N, Konzeluhova J, Kohout P, Hrdlicka L, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Clin Immunol (2014) 20:495–501. doi: 10.1016/j.clim.2013.12.024.

11. Beaulieu DB, Ananthakrishnan AN, Martin C, Roy A, Dubinsky MC, Sands BE, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. (2018) 16:99–105.

12. Duricova D, Dvorakova E, Hrdalys O, Mitrova K, Durilova M, Konzeluhova J, et al. Safety of Anti-TNFs therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis. (2019) 25:789–96. doi: 10.1093/ibd/iyz294.

13. Madhevan E, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, et al. Pregnancy and neonatal outcome after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. (2021) 160:1131–9.

14. Flanagan E, Wright EK, Hardikar W, Sparrow MP, Connell WR, Kamm MA, et al. Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and characterization of thiopurine metabolites and outcomes in exposed neonates. Aliment Pharmacol Ther. (2021) 53:810–20. doi: 10.1111/apt.16294.

15. Locke BA, Dasu T, Velsky JW. Laboratory diagnosis of primary immunodeficiencies. Clin Rev Allergy Immunol. (2014) 46:154–68.

16. Dasu T. Combined primary immune deficiency: diagnosis by clinical bow cytometry. MLO Med Labs Obs. (2015) 47:18–20.

17. Amariglio N, Lev A, Simon A, Rosenthal E, Spitzer Z, Orl E, et al. Molecular assessment of thymus capabilities in the evaluation of T-cell immunodeficiency. Pediatr Res. (2010) 67:211–6. doi: 10.1203/PDR.0b013e3181cfe554.

18. Somech R. T-cell receptor excision circles in primary immunodeficiencies and other T-cell immune disorders. Curr Opin Allergy Clin Immunol. (2011) 11:57–24. doi: 10.1097/ACI.0b013e328344c233a.

19. Devonshire AL, Makjha M. Approach to primary immunodeficiency. Allergy Asthma Proc. (2019) 40:465–9.

20. Douek DC, McFarland RD, Kreiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age during and the treatment of HIV Infection. Nature. (1998) 396:860–5.

21. Rechavi E, Lev A, Simon AJ, Stauber T, Daas S, Saraf-Levy T, et al. First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights. Front Immunol. (2017) 8:1448. doi: 10.3389/fimmu.2017.01448.

22. Ben-Horin S, Yavrozi M, Katz L, Koplyov U, Picard O, Fudim E, et al. The immunogenic part of infliximab is the Fab’12, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. (2011) 60:41–8. doi: 10.1136/gut.2009.201533.

23. Koplyov U, Mazor Y, Yavrozi M, Fudim E, Katz L, Cocos D. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. (2012) 18:1628–33. doi: 10.1002/ibd.21919.

24. Lev A, Simon AJ, Bareket M, Biorari B, Hutt D, Amariglio N, et al. The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients. PLoS One. (2012) 7:e30494. doi: 10.1371/journal. pone.0030494.

25. Jolving LR, Nielsen J, Beck-Nielsen SS, Nielsen RG, Friedman S, Kesmodel US, et al. The association between maternal chronic inflammatory bowel disease and long-term health outcomes in children: a nationwide cohort study. Inflamm Bowel Dis. (2017) 23:1440–6. doi: 10.1097/MIB.0000000000001146.

26. Madhevan U, Martin C, Sandler RS, Kane RS, Sunanda V, Dubinsky M, et al. PANO: a 1000 patients prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologics. Gastroenterology. (2012) 142:S349.

27. Gibert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. (2013) 108:1426–38.

28. Leung YPY, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumor necrosis factor therapy: state of the art and future directions. Can J Gastroenterol Hepatol. (2014) 28:855–9.

29. Marchionni R, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. (2013) 19:2591–602. doi: 10.3748/wjg.v19.i17.2591.

30. Kammerlander H, Nielsen J, Knudsen T, Kjeldsen J, Friedman S, Nørgård BM. Anti-TNFs during the third trimester of pregnancy in women with moderate severe inflammatory bowel disease and the risk of preterm birth and low birth weight. Inflamm Bowel Dis. (2017) 23:1916–23. doi: 10.1097/MIB.0000000000001234.

31. Oikonompoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies I inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. (2013) 14:1421–32. doi: 10.2174/138945011344990164.
32. Billmeier U, Dieterich W, Neurath M, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel disease. *World J Gastroenterol.* (2016) 22:9300–13.

33. Luu M, Bezenine E, Barkun A, Doret M, Michiels C, Degand T, et al. Safety of first year vaccination in children born to mother with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort. *Aliment Pharmacol Ther.* (2019) 50:1181–8. doi: 10.1111/apt.15504

34. Stam J, van Stuijvenberg M, Gruber C, Mosca F, Arslanoglu S, Chiric G, et al. Antibiotic use in infants in the first year of life in five European countries. *Acta Pediatr.* (2012) 101:929–34.

35. Broms G, Kieler H, Ekbom A, Gissler M, Hellgren K, Leinonen MK, et al. Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy. *Aliment Pharmacol Ther.* (2020) 52:843–54.

36. Norgard BM, Nielsen J, Friedman S. In utero exposure to thiopurines/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark. *Aliment Pharmacol Ther.* (2020) 52:829–42. doi: 10.1111/apt.15956

37. El-Matay W. Risk of attenuated live vaccines-induced infections in infants of mothers receiving anti-tumor necrosis factor agents for inflammatory bowel disease. *Gastroenterology.* (2016) 151:1250. doi: 10.1053/j.gastro.2016.08.065